Our Research

Biogen Idec capitalizes on the 30 years of research and development experience we have as a company and applies it to addressing the needs of people with hemophilia.

Our goal is to transform hemophilia management by researching long-lasting, fully recombinant clotting factors. Take a minute to see what we have planned for the future of hemophilia treatment in our robust pipeline, and then learn more about our clinical trials.